Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,145.03 USD
-5.16 (-0.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1,150.00 +4.97 (0.43%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
REGN 1,145.03 -5.16(-0.45%)
Will REGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
Other News for REGN
EU pharma committee takes positive view on AbbVie, Merck, others
Dupixent? (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
Regeneron/Sanofi Dupixent endorsed in EU for eosinophilic esophagitis for children
Regeneron, Sanofi announce CHMP adopts positive opinion for Dupixent
American Century Focused Dynamic Growth Fund Q2 2024 Commentary